Background

This study is conducted in patients with metastatic liver cancer, pancreatic cancer, biliary tract cancer, and gallbladder cancer. These cancers are difficult to detect early, have limited treatment options, and are associated with low survival rates.

Mechanism of Action

Guadecitabine is a DNA methyltransferase inhibitor that blocks enzymes required for tumor cell growth. Duvalumab is a PD‑L1 immune checkpoint inhibitor that enables T cells to recognize cancer cells. The combination is expected to provide synergistic effects by simultaneously inhibiting tumor growth and activating immunity.

Clinical Design and Expected Outcomes

The primary objective in the Phase Ib stage is to explore safety and determine the optimal dose, with the primary endpoint being adverse events and maximum tolerated dose. The study enrolls patients with metastatic liver, pancreatic, biliary, and gallbladder cancers, and will additionally assess tumor response rates and changes in immune biomarkers before and after treatment. The trial was initiated in February 2018, enrollment is now complete, and data analysis results are expected to be presented within the next two to three years.

Market and Investment Perspective

This combination has no commercially available product yet, and if successful it could introduce a new paradigm in the market for combined immune‑ and epigenetic‑targeted therapies. Because the research is university‑led, there is a high likelihood of early‑stage corporate partnerships or licensing agreements. Investors will closely monitor clinical progress and safety data, and valuation may vary depending on partnership outcomes.